Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

International Journal of Hematology
A TsuboiH Sugiyama

Abstract

The product of the Wilms tumor gene, WT1, is a universal tumor antigen. We performed WT1 peptide-based immunotherapy for a patient with multiple myeloma (MM). This patient was a 57-year-old woman with chemotherapy-resistant MM (Bence Jones kappa type). The patient received weekly intradermal injections of an HLA-A*2402-restricted 9-mer WT1 peptide emulsified with Montanide ISA 51 adjuvant for 12 weeks and achieved a minimal response according to European Group for Blood and Marrow Transplantation criteria without experiencing systemic adverse effects. The proportion of myeloma cells in the bone marrow (BM) decreased from 85% to 25%, and the amount of M protein in the urine decreased from 3.6 to 0.6 g/day after WT1 vaccination. Furthermore, a bone scintigram showed an improvement after the vaccination. As for immunologic parameters, the frequency of WT1 tetramer-positive cells among CD8+ T-cells, which was higher than in healthy donors, temporarily decreased at weeks 4 and 8 but increased at week 12, whereas the frequency of WT1 peptide-responding CD107a/b+ cells among WT1 tetramer-positive T-cells increased from 27.0% to 38.6% after the vaccination. After WT1 vaccination, the frequency of CXCR4+ cells among WT1 tetramer-positiv...Continue Reading

References

Apr 6, 1999·Japanese Journal of Cancer Research : Gann·Y OjiH Sugiyama
May 25, 2001·International Journal of Hematology·H Sugiyama
Oct 29, 2003·Journal of Immunological Methods·Michael R BettsRichard A Koup
Sep 2, 2004·Journal of Molecular Histology·Magda KuciaMariusz Z Ratajczak
Sep 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro OkaHaruo Sugiyama
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Taichi AzumaMasaki Yasukawa
Apr 28, 2005·International Journal of Cancer. Journal International Du Cancer·Hiroaki MushaIwao Sasaki

❮ Previous
Next ❯

Citations

May 23, 2012·Clinical & Developmental Immunology·Lu ZhangJochen Greiner
Sep 4, 2013·Immunotherapy·Frederick L LockeMohamed A Kharfan-Dabaja
Apr 17, 2010·Japanese Journal of Clinical Oncology·Haruo Sugiyama
Sep 18, 2015·Human Vaccines & Immunotherapeutics·Eva van DoornEelko Hak
Jun 2, 2018·Expert Review of Hematology·Jessica LiegelJacalyn Rosenblatt
Nov 1, 2008·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Yoshihiro Oka, Ichiro Kawase
Sep 10, 2014·International Journal of Cancer. Journal International Du Cancer·Lei WangMichael Schmitt
Sep 30, 2017·Journal of Immunotherapy·Rebecca Karp LeafDavid Avigan
Jan 23, 2019·Current Hematologic Malignancy Reports·Myo Htut
Jan 30, 2019·The Cancer Journal·Jacalyn Rosenblatt, David Avigan
Jun 8, 2012·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Toshinari MikamiYasunori Takeda
Nov 19, 2010·Expert Review of Hematology·Michael HudecekStanley R Riddell
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shaji K Kumar, Kenneth C Anderson
May 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacalyn RosenblattDavid Avigan
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jessica LiegelDavid Avigan
Feb 16, 2021·Frontiers in Oncology·Leona YamamotoKenneth Carl Anderson
Mar 4, 2021·International Immunopharmacology·Yujie JiangXin Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.